Case Report: A Recovered SARS CoV-2 Patient Protected From Reinfection

Abstract

The COVID-19 pandemic caused by SARS CoV-2 is a worldwide emergency, and is taking a substantial toll on human health, lives, and the global economy. Due to the novelty of this virus, no SARS CoV-2-specific treatments or licensed vaccines are available though few vaccines are undergoing clinical trials. Therefore, continued research into an effective vaccine is an urgent necessity. The reinfection of recovered patients is one of the major concerns of healthcare providers worldwide. Health authorities are currently seeking evidence of protection from reinfection in recovered individuals. This is the first case report in Saudi Arabia on a patient who was diagnosed as COVID-19-positive; recovered; and after successful recovery was protected against reinfection.

The seroprevalence of SARS-CoV-2 IgG antibodies among asymptomatic blood donors in Saudi Arabia

“…No globally approved vaccine exists yet, although a few are in various phases of clinical trial ( Chen et al, 2020a ). Several cases of reinfection have been reported, although protection from reinfection has also been reported ( Mahallawi, 2020 ). Consequently, the monitoring of seropositive cases at the international level will facilitate the establishment of conclusive data regarding the virus and its behavior in various populations.…”

Association of Viral Load in SARS-CoV-2 Patients With Age and Gender

“…Such a disease creates huge burden on health care providers and governments as that of MERS Co-V in 2012 ( 3 ). Additionally, the worries about re-infection is of a major concern, whoever, protection from reinfection has been reported ( 4 ).…”

A serological assay to detect human SARS-CoV-2 antibodies

“…Therefore, the presence of neutralising antibodies against the lethal SARS-CoV-2 in recovered individuals is presumed to be protective against re-infection. 25 …”